Novo Nordisk Sues Eli Lilly Over Alleged Misleading Advertising for Obesity Drugs

Novo Nordisk has filed a lawsuit against rival Eli Lilly in the U.S., alleging misleading advertising for its obesity treatments, including Zepbound and Mounjaro. The legal action occurs amid intense competition in the multi-billion dollar weight-loss drug market.